



Resource impact summary report

Resource impact

Published: 28 April 2026

www.nice.org.uk

Contents

Resource impact summary report	3
Guidance recommendation	3
Financial and capacity resource impact.....	3
Eligible population for ripretinib	3
Key information.....	4
About this resource impact summary report.....	4

Resource impact summary report

Guidance recommendation

See [NICE's recommendation on ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors](#).

Financial and capacity resource impact

The key drivers of resource impact are that:

- Usual treatment for advanced gastrointestinal stromal tumours (GISTs), after the tyrosine kinase inhibitors imatinib, sunitinib and regorafenib, is best supportive care. Before this recommendation, there were no lines of pharmacological treatment recommended after third-line treatment. Ripretinib introduces a fourth-line treatment option, so will result in additional drug costs.
- Ripretinib is an oral treatment but will need outpatient monitoring. Because the patient population is small, the impact on oncology clinics will be negligible.

The company has a [commercial arrangement](#). This makes ripretinib available to the NHS at a discount.

The payment mechanism for the technology is determined by the responsible commissioner and depends on whether the technology is classified as high cost.

Eligible population for ripretinib

NHS England data shows that 66 people had third-line treatment with regorafenib in 2024 to 2025. Clinical expert opinion suggests around 50% of this group would be eligible to have ripretinib at fourth line. So, the eligible population is estimated to be around 33 people. The uptake is expected to be 80% in year 3. Because the population is small, we have not produced a resource impact template.

Key information

Table 1 Key information

Time from publication to routine commissioning funding	90 days
Programme budgeting category	02B, upper GI
Commissioner	NHS England
Providers	NHS hospital trusts
Pathway position	Fourth line, after treatment with 3 or more kinase inhibitors

About this resource impact summary report

This resource impact summary report accompanies the [NICE technology appraisal guidance on ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors](#) and should be read with it.

ISBN: 978-1-4731-9458-8